Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | ALPG | P10696 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28902097 | 0.84 | CYP2C19 (0.67) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL11119737 | 0.81 | CYP2C19 (0.48) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL9150145 | 0.81 | CYP3A4 (0.70) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL12796854 | 0.81 | CYP1A2 (0.67) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL8410259 | 0.78 | CYP2C19 (0.60) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL18781368 | 0.78 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL22922266 | 0.78 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| Ristianol SCHEMBL10352649 | 0.78 | CYP2C19 (0.60) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL68470 | 0.77 | CYP2C19 (0.68) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL31058798 | 0.77 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488544-B1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | UNIV MONASH (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8748582-B2 | Affinity ligands and methods for protein purification | MONASH UNIVERSITY (AU) | 2014-06-10 | — | — | US | disclosed |
| US-8748582-B2 | Affinity ligands and methods for protein purification | MONASH UNIVERSITY (AU) | 2014-06-10 | — | — | US | disclosed |
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY | 2012-10-11 | — | — | US | disclosed |
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY | 2012-10-11 | — | — | US | disclosed |
| WO-2011044637-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY (AU) | 2011-04-21 | — | — | WO | disclosed |
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |
| US-4599336-A | BRONCHODILATOR, THROMBOXANE SYNTHETASE INHIBITOR, ANTIARRHYTHMIA | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4551460-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-05 | — | — | US | disclosed |
| US-4104382-A | (((THIAZOLYL-, ISOTHIAZOLYL- OR PYRIDYLALKYL)THIO)ALKYL)GUANIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | disclosed |
| US-4080459-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-03-21 | — | — | US | disclosed |
| US-4067984-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-10 | — | — | US | disclosed |
| US-4013769-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-03-22 | — | — | US | disclosed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MAX, SPR, CCL2 | CYP1A2 3926/4885CYP2D6 4223/4885CYP2C19 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.